Pirfenidone encapsulated in succinylated gelatin-coated liposomes exhibits sustained antifibrotic effects in vitro models of renal, pulmonary, and hepatic fibrosis
- 8 May 2025
- journal article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (7) , 103819
Abstract
No abstract availableKeywords
Funding Information
- Northern Advancement Center for Science and Technology (2020-ST-32)
- Akiyama Life Science Foundation
- Japan Society for the Promotion of Science (22K19941, JP17H02178, 18K12066, JP18K06603)
- Suhara Memorial Foundation
This publication has 51 references indexed in Scilit:
- Transwell In Vitro Cell Migration and Invasion Assays2023
- Liposomes as biocompatible and smart delivery systems – the current stateAdvances in Colloid and Interface Science, 2022
- The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence ReviewPharmacoEconomics, 2018
- The Bleomycin Model of Pulmonary Fibrosis2017
- Recent advances in the use of gelatin in biomedical researchBiotechnology Letters, 2015
- Pharmacokinetic evaluation of tissue distribution of pirfenidone and its metabolites for idiopathic pulmonary fibrosis therapyBiopharmaceutics & Drug Disposition, 2014
- Novel mineralized heparin–gelatin nanoparticles for potential application in tissue engineering of boneJournal of Materials Science: Materials in Medicine, 2013
- Pharmacokinetics and metabolism of intravenous pirfenidone in sheepBiopharmaceutics & Drug Disposition, 2008
- Simple and highly sensitive determination of free fatty acids in human serum by high performance liquid chromatography with fluorescence detectionBiomedical Chromatography, 1992
- Characterization of collagen peptides by sodium dodecylsulfate-polyacrylamide electrophoresisAnalytical Biochemistry, 1971